Literature DB >> 11751595

Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures.

D Gaddy-Kurten1, J K Coker, E Abe, R L Jilka, S C Manolagas.   

Abstract

Using primary murine bone marrow cell cultures, we demonstrate that inhibin suppresses osteoblastogenesis and osteoclastogenesis. In contrast, activin supports osteoblast formation (by alkaline phosphatase-positive and mineralized colony formation); and activin also stimulates osteoclast formation (as measured by staining tartrate-resistant acid phosphatase-positive multinucleated cells). Inhibin, the activin antagonist follistatin, and the bone morphogenetic protein antagonist noggin can all suppress endogenous activin accumulation in bone marrow cultures. Associated with this decrease in activin is the loss of mineralized osteoblastic colony formation (colony forming unit-osteoblast; CFU-OB). However, exogenous activin administration, even in the presence of noggin, permits both alkaline phosphatase-positive and CFU-OB colony formation in vitro. In contrast, the stimulatory effects of locally produced activin on osteoblast and osteoclast development are not likely to be dominant over the suppressive effects of gonadally derived inhibin. The suppressive effect of inhibin is maintained in the presence of either activin or bone morphogenetic protein, suggesting the presence of a distinct inhibin-specific receptor. Taken together, the direct regulation of osteoblastogenesis and osteoclastogenesis by inhibin and activin in vitro suggest that changes in the inhibin/activin ratio detected by bone marrow cells, during the perimenopausal transition, contribute to altered cell differentiation and may be associated with the increased bone resorption observed at this time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751595     DOI: 10.1210/endo.143.1.8580

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  61 in total

1.  BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.

Authors:  Shoichiro Kokabu; Laura Gamer; Karen Cox; Jonathan Lowery; Kunikazu Tsuji; Regina Raz; Aris Economides; Takenobu Katagiri; Vicki Rosen
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

Review 3.  Reproductive hormones and bone.

Authors:  Kristy M Nicks; Tristan W Fowler; Dana Gaddy
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

Review 4.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

5.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

Review 6.  New treatment modalities in osteoporosis.

Authors:  Ernesto Canalis
Journal:  Endocr Pract       Date:  2010 Sep-Oct       Impact factor: 3.443

Review 7.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

9.  Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.

Authors:  Ethan Kellum; Harlan Starr; Phonepasong Arounleut; David Immel; Sadanand Fulzele; Karl Wenger; Mark W Hamrick
Journal:  Bone       Date:  2008-09-13       Impact factor: 4.398

10.  New insights: elevated follicle-stimulating hormone and bone loss during the menopausal transition.

Authors:  Mone Zaidi; Harry C Blair; Jameel Iqbal; Terry F Davies; Ling Ling Zhu; Alberta Zallone; Li Sun
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.